DYNAMIC
Craftsmanship Alchemy: Taming the "Twin" Impurities in Orforglipron
WUHAN HITECK BIOPHARMACEUTICAL CO., LTD
Wuhan Hiteck Biopharmaceutical Co., Ltd. is a publicly listed biopharmaceutical company (Shenzhen Stock Exchange: 300683) dedicated to the discovery and development of innovative biologics and small-molecule therapeutics. Originating from the Medical School of Wuhan University, Hiteck has built an integrated R&D and manufacturing infrastructure supporting end-to-end drug development and translation...
Hiteck Biopharmaceutical National Class 1 Innovative Drug Selected as a “61020” Landmark Innovation Achievement of Hubei Province
2026-01-06 14:10:21
Congratulations to Professor Liu Wenbo on publishing significant research findings in《Nature Communications》
2026-01-05 17:00:43
PRODUCTS
The company is based on the R & D and production of drugs in the field of nervous system and oncology
A national class I biological new drug, mouse nerve growth factor for injection (Jinlujie), and a class I genetic engineering biological new drug, recombinant mutant human tumor necrosis factor related apoptosis inducing ligand (CPT) have been put on the market.
INNOVATIVE RESEARCH AND DEVELOPMENT
The company is a high-tech enterprise in Hubei Province. There are post doctoral mobile workstations approved by the Ministry of human resources and social security of the people's Republic of China, and "Hubei rare disease drug engineering technology research center" and "Hubei high tech innovative enterprise" approved by the provincial science and technology department. Five basic technology platforms have been established, and pilot bases have been established to promote the industrialization of relevant achievements and efficient transformation to the market.
Copyright © 武汉海特生物制药股份有限公司 All Rights Reserved. 鄂ICP备05001864号-1 网站建设：中企动力 武汉
TOP